Last Week: Pump up the volume

In the seven days between Dec. 8 and Dec. 16, the shares dropped from $6 to $2.875. The price had rebounded to $3.50 prior to the FDA letter, still well off the $10.875 it hit on Sept. 19 after the FDA's Oncologic Drugs Advisory Committee unanimously recommended approval for Paxene.

NPRO's share volume also ballooned the week prior to receiving the letter, trading nearly 1.3 million shares, a daily average of 260,000 shares. NPRO's average daily volume was 88,600 shares in the fourth quarter...